Janssen Scientific Affairs, LLC - Recruiting 18 years or older. - A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine and Rilpivirine in HIV-1 Infected Pregnant Women.
Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (ò 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany.
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 45 years. - A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation.
XF-73 in 4% Klucelr gel; XF-73 in 2% Klucelr gel; Placebo in 4% Klucelr gel
Janssen-Cilag International NV - Recruiting 18 years or older. - A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF).
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A to 17 years. - Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents.
Dolutegravir (DTG) tablet formulation; DTG oral pediatric granules taken as suspension or granules
ViiV Healthcare - Recruiting 2 years to 18 years. - An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2 - <18 Years Of Age.
ViiV Healthcare - Recruiting 18 years or older. - An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients.
Maraviroc along with an optimized background antiretroviral drug regimen; Optimized background antiretroviral drug regimen without maraviroc
University of North Carolina, Chapel Hill - Recruiting 18 years or older. - CID 1213 - Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women After Switching to Fixed Dose Combination of Rilpivirine, Emtricitabine and Tenofovir DF.
Gilead Sciences - Recruiting 18 years or older. - A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults.
Rockefeller University - Recruiting 18 years to 65 years. - A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers.
1 mg/kg, single dose IV administration of 3BNC117; 3 mg/kg, single dose IV administration of 3BNC117; 10 mg/kg, single dose IV administration of 3BNC117
Bristol-Myers Squibb - Recruiting 18 years to 55 years. - Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects.
BMS-955176; Placebo matching with BMS-955176; Atazanavir; Ritonavir; Tenofovir; Emtricitabine
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years or older. - A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women.
Gilead Sciences - Recruiting 12 years to 17 years. - A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
Hospital Clinic of Barcelona - Recruiting 18 years or older. - Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy.
Hospital Clinic of Barcelona - Recruiting 18 years or older. - Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 61 years. - Screening and Recruitment for HIV-associated Neurocognitive Disorders (HAND) Studies and an Evaluation of HIV-associated Neurocognitive Disorders in Virologically Controlled Patients With CD4 Nadir of Less Than 200 Cells Per mm (3).
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 65 years. - A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection.
HIV-1 Multiantigen pDNA Vaccine; Human IL-12 pDNA; In Vivo Electroporation using the TriGri; rVSVIN HIV Gag Vaccine; Placebo
Erasmus Medical Center - Recruiting 18 years or older. - Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial..
University of Toronto - Recruiting 18 years or older. - Pilot-testing a Group-level Intervention to Reduce Risk for Sexual Transmission of HIV/STIs Among Lesbian, Bisexual and Queer Women and Other Women Who Have Sex With Women in Calgary and Toronto.
Adapted Many Men, Many Voices (3MV) group level intervention; A group-based HIV/STI prevention intervention for women who have sex with women
Gilead Sciences - Recruiting N/A to 17 years. - A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG)Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects.
Medical Research Council - Recruiting 18 years or older. - Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD).
Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
Dartmouth-Hitchcock Medical Center - Recruiting 18 years to 65 years. - A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG.
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 45 years. - A Phase 1, Open-Labeled Study of the Safety, Tolerability and Pharmacokinetics of Aerosolized Colistimethate Sodium After Multiple Doses Administered Separately or in Combination With Intravenous Colistimethate Sodium in Healthy Adults.
Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients.
University of North Carolina, Chapel Hill - Recruiting 18 years to 49 years. - A Feasibility Study to Assess Protection of Vaginal and Cervical Tissues From Ex-Vivo HIV-1 Challenge Following Oral Administration of Maraviroc and Tenofovir.
St Stephens Aids Trust - Recruiting 18 years to 65 years. - The Immunological Impact of Adding Hydroxychloroquine in Patients With Discordant CD4+ Cell Responses to Suppressive HAART: A Phase I Pilot Study..
University of North Carolina, Chapel Hill - Recruiting 18 years or older. - CIDRZ-1220 Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA).
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years or older. - A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications.
KineMed - Recruiting 18 years or older. - Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases.
Valme University Hospital - Recruiting 18 years or older. - Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
Deutsche Luft und Raumfahrt - Recruiting 18 years or older. - Incidence, Prevalence, Spectrum of HPV-types, and Viral Load Determination of High-risk Human Papillomavirus Infection of the Oral Cavity in HIV-infected Men Who Have Sex With Men.
Oral swabs for HPV-typing and high-risk HPV-determination
Deutsche Luft und Raumfahrt - Recruiting 18 years or older. - Evaluation of Viral Load Determination and Other Biomarkers of High Risk HPV-Types as a Marker for Progression of Perianal HPV-infections in HIV-positive Men Who Have Sex With Men.
Smear and biopsy testing for HPV-types and viral load
Gilead Sciences - Recruiting 3 Months to 17 years. - A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered With Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects.
University Hospital, Bonn - Recruiting 18 years or older. - Myocardial T1-mapping and T1-derived Extracellular Volume Fraction (ECV) in HIV-infection Patients With Chronic High and Low CD4+ Counts and in a Healthy Control Group.
Centers for Disease Control and Prevention - Recruiting 20 years or older. - Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers.
Washington University School of Medicine - Recruiting 18 years to 65 years. - A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia (100 mg/d) for Reducing Inflammation and Increasing Endothelial Progenitor Cell Number in Human Immunodeficiency Virus (HIV) Infected Men and Women With Insulin Resistance and Central Adiposity..
Columbia University - Recruiting 1 Month to 12 years. - Enhanced Surveillance and 2 Year Outcomes of Children Enrolled on Antiretroviral Therapy (ART) in Public Health Facilities in the Eastern Cape Province, South Africa.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years. - VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01),Administered Intravenously or Subcutaneously to Healthy Adults.
Gen-Probe, Incorporated - Recruiting 15 years or older. - Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay.
University of North Carolina, Chapel Hill - Recruiting 18 years to 65 years. - A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy.
InnaVirVax - Recruiting 18 years to 60 years. - Assessment of the Therapeutic Properties of the VAC-3S Immunoprotective Vaccine When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study.
Bionor Immuno AS - Recruiting 18 years to 55 years. - A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART)..
Part A: lenalidomide dose escalation; Part B: lenalidomide; Part B: lenalidomide placebo
University of Washington - Recruiting 16 years or older. - An Evaluation of Strategies to Increase Testing and Linkages of HIV Positive Individuals to Care and HIV Negative Men to Male Circumcision in Sub-Saharan Africa.
Karolinska Institutet - Recruiting N/A to 12 years. - A Randomized Controlled Trial to Assess the Effect of Group Peer Support to Children With HIV in Relation to Adherence, Virological Treatment Failure as Well as Physical Development.
Gilead Sciences - Recruiting 12 years to 17 years. - A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
Janssen Research & Development, LLC - Recruiting 18 years to 45 years. - Phase 1 Open Label Safety, Acceptability, Pharmacokinetic and ex Vivo Pharmacodynamic Study of TMC278 Long Acting (LA) Administered Intramuscularly to HIV-1 Seronegative Individuals.
Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 64 years. - Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice.
Sanofi - Recruiting 18 years to 55 years. - An Open-label, Non-randomized, Single Sequence, Two Periods, Four-treatment, Three Parallel Groups Pharmacokinetic Interaction Study of Repeated Oral Doses (Daily or Weekly Regimen) of Rifapentine on ATRIPLAT (Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate) Given to HIV+ Patients.
Gilead Sciences - Recruiting N/A or older. - A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication Nested in the Antiretroviral Pregnancy Registry.
ViiV Healthcare - Recruiting 18 years or older. - A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Nave Women.
AIDS Clinical Trials Group - Recruiting 18 years or older. - An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <350 Cells/mm3.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy.
Taipei Veterans General Hospital, Taiwan - Recruiting 20 years to 60 years. - An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-nave Patients With HIV-1 Infection.
Bristol-Myers Squibb - Recruiting 18 years or older. - Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment nave Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV.
Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years. - Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
Columbia University - Recruiting 16 years or older. - Mother Infant Retention for Health: Evaluation of a Multicomponent Strategy to Link and Retain Newly Identified HIV-infected Pregnant Women and Their Infants Throughout the Antenatal and Post-partum Period.
Fundacion SEIMC-GESIDA - Recruiting 18 years or older. - Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
University of Zurich - Recruiting 18 years or older. - A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS).
International AIDS Vaccine Initiative - Recruiting 18 years to 50 years. - A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers.
Beijing 302 Hospital - Recruiting 18 years to 60 years. - Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection.
Duke University - Recruiting 18 years to 75 years. - Treatment of Acute HIV Infection With the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate, A Pilot Study of Response to Therapy and HIV Pathogenesis.
Hospital Clinic of Barcelona - Recruiting 18 years or older. - Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up.
AIDS Community Research Initiative of America - Recruiting 18 years to 65 years. - A Double Blind, Randomized Trial to Evaluate the Safety and Efficacy of 8 Weekly Doses of Prolastinr-C (à1Proteinase Inhibitor, à1PI) in Human Immunodeficiency Virus-Infected Subjects Who Are 18 to 65 Years of Age and Who Are on Antiretroviral Therapy.
University of Cape Town - Recruiting 18 years or older. - A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings.
Imperial College London - Recruiting 60 years or older. - An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age.
Tuberculosis Research Centre, India - Recruiting 18 years or older. - A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis.
St. James's Hospital, Ireland - Recruiting 18 years or older. - An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-nave, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone.
Medical Research Council - Recruiting N/A to 3 Days. - An Open Randomized Phase I/II Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1-infected Mothers.
Istituto Superiore di Sanita - Recruiting 18 years to 45 years. - A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape.
Imperial College London - Recruiting 18 years or older. - A Randomised, Open Label, Prospective Study to Assess Two Different Therapeutic Strategies Following First Treatment Failure in HIV-1 Infected Subjects.
Darunavir, Ritonavir, Truvada; Darunavir, Ritonavir and Etravirine
Istituto Superiore di Sanita - Recruiting 18 years or older. - Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy.
Indinavir in association with Vinblastina +/- Bleomicina
University of Texas Southwestern Medical Center - Recruiting 18 years or older. - Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations.
Centers for Disease Control and Prevention - Recruiting 15 years or older. - Preventing Serious Neonatal and Maternal Peripartum Infections in Developing Country Settings With a High Prevalence of HIV Infection: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa.
Chlorhexidine; Birth canal wipe; sterile water external genital wipe
407 Doctors - Recruiting 18 years or older. - A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily.
once daily minimum 3-drug regimen of anti-retroviral medications